title: Evaluation of Combinations of 4'-Ethynyl-2-Fluoro-2'-Deoxyadenosine with Clinically Used Antiretroviral Drugs.
abstract: Drug combination studies of 4'-ethynyl-2-fluoro-2'-deoxyadenosine (EFdA) with FDA-approved drugs were evaluated by two different methods, MacSynergy II and CalcuSyn. Most of the combinations, including the combination of the two adenosine analogs EFdA and tenofovir, were essentially additive, without substantial antagonism or synergism. The combination of EFdA and rilpivirine showed apparent synergism. These studies provide information that may be useful for the design of EFdA combination regimens for initial and salvage therapy assessment.
authors.affiliation: Christopher Bond Life Sciences Center, Department of Molecular Microbiology and Immunology, University of Missouri School of Medicine, Columbia, Missouri, USA.|AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan.
authors.forename: Atsuko
authors.initials: A
authors.lastname: Hachiya
authors.affiliation: Department of Microbiology and Molecular Genetics, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
authors.forename: Aaron B
authors.initials: AB
authors.lastname: Reeve
authors.affiliation: Christopher Bond Life Sciences Center, Department of Molecular Microbiology and Immunology, University of Missouri School of Medicine, Columbia, Missouri, USA.
authors.forename: Bruno
authors.initials: B
authors.lastname: Marchand
authors.affiliation: Christopher Bond Life Sciences Center, Department of Molecular Microbiology and Immunology, University of Missouri School of Medicine, Columbia, Missouri, USA.
authors.forename: Eleftherios
authors.initials: E
authors.lastname: Michailidis
authors.affiliation: Christopher Bond Life Sciences Center, Department of Molecular Microbiology and Immunology, University of Missouri School of Medicine, Columbia, Missouri, USA.
authors.forename: Yee Tsuey
authors.initials: YT
authors.lastname: Ong
authors.affiliation: Christopher Bond Life Sciences Center, Department of Molecular Microbiology and Immunology, University of Missouri School of Medicine, Columbia, Missouri, USA.
authors.forename: Karen A
authors.initials: KA
authors.lastname: Kirby
authors.affiliation: Christopher Bond Life Sciences Center, Department of Molecular Microbiology and Immunology, University of Missouri School of Medicine, Columbia, Missouri, USA.
authors.forename: Maxwell D
authors.initials: MD
authors.lastname: Leslie
authors.affiliation: AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan.
authors.forename: Shinichi
authors.initials: S
authors.lastname: Oka
authors.affiliation: Division of Emerging Infectious Diseases, Tohoku University, Tohoku Medical Megabank Organization, Miyagi, Japan.
authors.forename: Eiichi N
authors.initials: EN
authors.lastname: Kodama
authors.affiliation: Magee-Womens Research Institute.|Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
authors.forename: Lisa C
authors.initials: LC
authors.lastname: Rohan
authors.affiliation: Department of Hematology and Infectious Diseases, Kumamoto University, Kumamoto, Japan.|Experimental Retrovirology Section, HIV/AIDS Malignancy Branch, National Institutes of Health, Bethesda, Maryland, USA.
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Mitsuya
authors.affiliation: Department of Microbiology and Molecular Genetics, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
authors.forename: Michael A
authors.initials: MA
authors.lastname: Parniak
authors.affiliation: Christopher Bond Life Sciences Center, Department of Molecular Microbiology and Immunology, University of Missouri School of Medicine, Columbia, Missouri, USA sarafianoss@missouri.edu.|Department of Biochemistry, University of Missouri, Columbia, Missouri, USA.
authors.forename: Stefan G
authors.initials: SG
authors.lastname: Sarafianos